Replimune Group (NASDAQ:REPL) Rating Lowered to "Hold" at Cantor Fitzgerald

Replimune Group (NASDAQ:REPL - Get Free Report) was downgraded by Cantor Fitzgerald from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on REPL. Piper Sandler cut Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a research note on Tuesday. Jefferies Financial Group reduced their price objective on Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday. Leerink Partners restated a "market perform" rating and set a $3.00 price target on shares of Replimune Group in a research note on Tuesday. Wedbush restated a "neutral" rating and set a $4.00 price target (down from $19.00) on shares of Replimune Group in a research note on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of Replimune Group in a research note on Thursday, July 3rd. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.38.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $2.81 on Tuesday. The stock has a market capitalization of $216.62 million, a price-to-earnings ratio of -0.92 and a beta of 0.61. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The firm's 50 day simple moving average is $9.62 and its 200-day simple moving average is $10.46. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.25) earnings per share. Analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 3,749 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $30,179.45. Following the transaction, the insider owned 128,296 shares of the company's stock, valued at $1,032,782.80. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Andrew Schwendenman sold 3,287 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the transaction, the chief accounting officer directly owned 68,284 shares in the company, valued at approximately $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of REPL. Boxer Capital Management LLC purchased a new position in Replimune Group in the 4th quarter worth $21,754,000. Tang Capital Management LLC raised its position in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after purchasing an additional 1,500,000 shares during the period. Price T Rowe Associates Inc. MD raised its position in Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after purchasing an additional 1,083,633 shares during the period. MPM Bioimpact LLC purchased a new position in shares of Replimune Group in the fourth quarter valued at about $11,504,000. Finally, RTW Investments LP increased its position in shares of Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after acquiring an additional 931,223 shares during the period. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.